NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced ...

Researchers have identified covert deletions of the proximal FXN gene that standard testing mistakes for identical repeat ...

A year-long Dutch study shows the PROM-Ataxia questionnaire validly captures disease burden in spinocerebellar ataxia, even ...

A monthly snapshot of FDA activity involving therapies used in the prevention, diagnosis, and treatment of neurologic conditions.

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that its Board of Directors, at a meeting held on October 5, 2026, ...

Taiwan-listed emerging biotech AnnJi (7754.TW) announced that its lead drug candidate AJ201 has received clearance from the U.S. Food and ...

Synapticure CEO and cofounder Sandra Abrevaya explains how the company's virtual ataxia program aims to address long waits ...

Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow ...

Genezen, a gene therapy contract development and manufacturing organization (CDMO), today announced a partnership with Nevena ...

Lexeo Therapeutics has signed an agreement to acquire Mantle Therapeutics and launched several new collaborations aimed at ...

A Hartlepool woman campaigning for access to a life-enhancing drug says she is proud after a petition secured 100,000 ...

Friedreich’s ataxia patients met with staff from Tallaght Hospital last week who explained the limitations in the current system around administering Skyclarys.